FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer

INTRODUCTION: The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti-programmed death-ligand 1 (PD-L1) atezolizumab in advanced non-small-cell lung cancer (NSCLC) selected by tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression. METHODS: Patients with PD-L1...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Thorac Oncol
Главные авторы: Spigel, David R., Chaft, Jamie E., Gettinger, Scott, Chao, Bo H., Dirix, Luc, Schmid, Peter, Chow, Laura Q. M., Hicks, Rodney J., Leon, Larry, Fredrickson, Jill, Kowanetz, Marcin, Sandler, Alan, Funke, Roel, Rizvi, Naiyer A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455890/
https://ncbi.nlm.nih.gov/pubmed/29775807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.05.004
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы